Full Press Release Details
INDIANAPOLIS , May 22, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro Injection has a 50 percent lower list price than its identical medicine, Humalog ® U-100 (insulin lispro injection) and is available in both a vial and KwikPen ® . Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog.
In March, Lilly announced plans to introduce Insulin Lispro Injection, which fills another gap in the healthcare system. The people who are most likely to benefit from Insulin Lispro Injection are Medicare Part D beneficiaries, people with high-deductible health plans and the uninsured who use Humalog.
"The availability of Lilly's Insulin Lispro Injection is important progress that helps more people afford their insulin," said Mike Mason , senior vice president, Connected Care and Insulins. "Lilly will continue to work with health plans, wholesalers, employers and the government to work toward permanent solutions that will help every person with diabetes afford their medicines."
Currently, about 95 percent of people in the U.S. pay $95 or less a month for their Humalog prescription and 43 percent pay $0 at the retail pharmacy. With the launch of Insulin Lispro Injection, even more people will pay lower amounts at the pharmacy. Because most insurance plans provide affordable copays for chronic medicines that are much lower than list price, people should ask their pharmacist whether Insulin Lispro Injection or Humalog is the lower-cost option for them. People with additional questions can also contact the Lilly Diabetes Solution Center at (833) 808-1234 from 9 am to 8 pm EST Monday through Friday to speak with a live representative.
Insulin Lispro Injection has a list price of $137.35 per vial and $265.20 for a package of five KwikPens. In addition to wholesaler contracts that have been secured, Lilly is working with payers to gain broad insurance coverage for Insulin Lispro Injection.
"The current healthcare system isn't working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine," Mason said. "But even one person with diabetes who can't afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved."
Indication for Humalog® (insulin lispro) and Insulin Lispro Injection Humalog and Insulin Lispro Injection are used to treat people with diabetes for the control of high blood sugar.
Important Safety Information for Humalog® (insulin lispro) and Important Safety Information for Insulin Lispro Injection
What is the most important information I should know about Humalog and Insulin Lispro Injection?
Who should not take Humalog or Insulin Lispro Injection?
Before using Humalog or Insulin Lispro Injection, what should I tell my healthcare providers?
How should I use Humalog or Insulin Lispro Injection?
What are the possible side effects of Humalog or Insulin Lispro Injection?
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Humalog and Insulin Lispro Injection are available by prescription only.
For additional information, talk to your healthcare providers and please click to access Humalog Full Prescribing Information and Patient Prescribing Information .
For additional information, talk to your healthcare providers and click to access Insulin Lispro Injection Full Prescribing Information and Patient Prescribing Information .
Please see Instructions for Use included with Humalog and Insulin Lispro Injection products.
HI IL CON ISI 04MAR2019
About Diabetes Approximately 30 million Americans 1 and an estimated 425 million adults worldwide have diabetes. 2 Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone. 1 Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels . P-LLY
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Insulin Lispro Injection and reflects Lilly's current beliefs. As with any pharmaceutical product, there are risks and uncertainties related to the commercialization and regulation of Insulin Lispro Injection and authorized generics. Among other things, there can be no guarantee that individual patient experiences will be consistent with intended results or that Lilly will realize the benefits described in this press release. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Humalog ® and KwikPen ® are registered trademarks of Eli Lilly and Company, its subsidiaries, or affiliates.
Refer to: Greg Kueterman ; [email protected] ; 317.277.4021 (Lilly Diabetes Communications) Dani Barnhizer ; [email protected] ; 317.276.3598 (Lilly Diabetes Communications) Kevin Hern ; [email protected] ; 317.277.1838 (Investor Relations)
SOURCE Eli Lilly and Company